Qsymia vs Wegovy: Oral Medication or GLP-1 Treatment?
Qsymia is an oral phentermine/topiramate extended-release combination, while Wegovy is semaglutide GLP-1 treatment. Wegovy produced greater average loss in major trials, but Qsymia can be an effective and potentially more affordable oral option.
Comparison at a glance
| Feature | Qsymia | Wegovy |
|---|---|---|
| Form | Daily capsule | Weekly injection or approved daily tablet |
| Mechanism | Sympathomimetic plus anticonvulsant | GLP-1 receptor agonist |
| Average effect | Among the stronger approved oral options | Greater average loss in major obesity trials |
| Key cautions | Pregnancy, heart rate, mood, cognition, glaucoma, stones | GI effects, MTC/MEN2, gallbladder, pancreas, dehydration |
| Cost | Generic-component strategies may reduce cost but are not identical | Coverage and formulation drive cost |
When Qsymia may fit
Qsymia may suit an eligible patient who prefers an oral medicine, does not have relevant contraindications and needs a potentially lower-cost plan. Pregnancy testing and prevention are critical because topiramate exposure can cause fetal harm.
When Wegovy may fit
Wegovy may receive priority when greater average weight reduction, cardiovascular evidence, non-stimulant treatment or an oral semaglutide pathway is important. Gastrointestinal tolerance and continued access must be considered.
What to expect from a W8MD medication evaluation
The first step is not choosing a brand from an advertisement. W8MD reviews weight history, previous diets and prescriptions, medication allergies, blood pressure, pulse, sleep symptoms, glucose status, relevant laboratory results, cardiovascular history, gastrointestinal symptoms, kidney and liver concerns, pregnancy plans and current medicines. This helps identify contraindications and realistic alternatives.
The treatment plan can include a lower-cost traditional prescription, an FDA-approved incretin medicine, structured nutrition, meal replacements, a medically supervised very-low-calorie diet for selected patients, home sleep-apnea testing or a combination of services. Follow-up assesses appetite response, adverse effects, hydration, protein intake, bowel symptoms, blood pressure, muscle preservation and progress toward health-centered goals. A dose is not increased simply because a calendar date arrives.
Affordable W8MD treatment pathways
Semaglutide
From $29.99/week when insurance is accepted for qualifying visits. Self-pay pathways start from $59.99/week.
Tirzepatide
From $45/week when insurance is accepted for qualifying visits. Self-pay pathways start from $69.99/week.
Traditional prescriptions
Phentermine, topiramate, Qsymia, Contrave, diethylpropion, phendimetrazine and orlistat may be considered when clinically appropriate.
Pricing notice: Starting prices are not guaranteed for every patient or dose. Visit, medication, laboratory, supply, shipping, copay, deductible and dose costs may be separate. Insurance coverage of a visit does not guarantee pharmacy coverage.
Medication safety and supervision
Prescription obesity treatment requires an individualized evaluation. Common considerations include pregnancy, cardiovascular disease, blood pressure, kidney and liver health, gastrointestinal disease, gallbladder and pancreatic history, glaucoma, mental health, diabetes medicines, controlled-substance risk and drug interactions. Product-specific FDA labeling controls.
Frequently asked questions
Which works better on average?
Wegovy produced greater average loss in separate major trials.
Which costs less?
Qsymia or generic components may cost less, but formulation and monitoring matter.
Can Qsymia be used during pregnancy?
No. It can cause fetal harm and requires strict pregnancy precautions.
Related Philadelphia and W8MD resources
Philadelphia services
WikiMD encyclopedia
How W8MD Philadelphia can help
W8MD physicians have more than 20 years of clinical experience and compare medical conditions, contraindications, previous attempts, appetite patterns, sleep, cultural food preferences, insurance coverage, patient preferences and long-term cost. Care can include medication, structured nutrition, a medically supervised VLCD for selected patients, sleep-apnea evaluation, muscle-preservation planning and maintenance.
1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115
Phone: 215-676-2334
Serving Northeast Philadelphia, Bucks County, Montgomery County, Delaware County, nearby Pennsylvania communities and South Jersey, subject to clinical and licensure requirements.
Contact W8MD Philadelphia
Use this form for nonurgent appointment and service questions.